Abstract 5520
Background
Chemotherapy‐induced nausea and vomiting (CINV) continue to be a clinical problem, particularly in the delayed phase. CINV lack of control worsens the quality of life of patients and it is associated with complications increasing costs for healthcare services. CINV app is a free service addressed to patients treated with emetogenic chemotherapy (CT), empowering patients to report CINV impact in life and relevant information. This study aims to evaluate the usability and acceptability of a smartphone app to improve CINV management in patients receiving CT.
Methods
We used 4‐dimensions test (content, graphic design, navigation and clinical utility) to evaluate APP’s usability and acceptability. Clinical and technical researchers worked together to develop the app’s test. 44 oncology nurses of 33 representative Spanish hospitals were invited to participate (from 31st January to 5th April 2019) enrolling a total amount of 116 oncology patients for testing purposes. After using the app for a chemo cycle the patient was asked to fulfil an online usability test.
Results
Described in the table.Table: CN2
Average of patients that agree for each dimension
Variables | Results (%) |
---|---|
Contents | 81% |
Navigation | 79% |
Graphic design | 83% |
Utility | 90% |
N = 116 Oncology chemo patients level agreement 83% of patients consider this app useful for them and 86% believe it would help to improve CINV management. 94% of patients would recommend it to other patients.
Conclusions
The CINV app addresses main concerns for patients receiving chemotherapy such as the clinical situation and individual emetic risk of patient or complexity of the prescribed antiemetic regimen and impact of CINV in patients daily life. By soliciting feedback from oncology patients, we ensured that the app was acceptable and beneficial for them although some improvement points were suggested. Reporting of symptoms after CT enhances CINV management, self‐care, and participation without being a burden to patients, indicating that app can be used in clinical practice by patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vifor Pharma España SL.
Funding
Vifor Pharma España SL.
Disclosure
P. Fernandez: Advisory / Consultancy, advisor activities: Vifor Pharma España. All other authors have declared no conflicts of interest.
Resources from the same session
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract